Skip to main content
SpringerLink
Log in

Interaction of Natural Products with Medication and Nutrients

  • Chapter
  • First Online:
Handbook of Drug-Nutrient Interactions

Part of the book series: Nutrition and Health ((NH))

  • 2982 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nutrition Business Journal Supplement Business Report 2007. Summary available at: http://nbj.stores.yahoo.net/nbjsubure20.html. Accessed February 20 2008.

  2. Dietary Supplement Health and Education Act (DSHEA), Public Law 103–417, 25 October 1994; Codified at 42USC 287C-11.

    Google Scholar 

  3. Mihoces G. Ephedrine under baseball’s microscope. USA Today Febrary 20, 2003. http://www.usatoday.com/sports/baseball/2003-02-20-cover-ephedrine-baseball_x.htm.

  4. Associated Press. Medical examiner: Ephedra a factor in Bechler death. USA Today, March 13, 2003 http://www.usatoday.com/sports/baseball/al/orioles/2003-03-13-bechler-exam_x.htm.

  5. Charatan F. Ephedra supplement may have contributed to sportsman’s death. BMJ 2003;326(7387):464.

    Article  Google Scholar 

  6. Fontanarosa PB, Rennie D, DeAngelis CD. The need for regulation of dietary supplements—lessons from ephedra. [Editorial]. JAMA 2003;289(12):1568–1570.

    Article  Google Scholar 

  7. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289(12):1537–1545.

    Article  CAS  Google Scholar 

  8. U.S.Food and Drug Administration–White paper on Ephedra. Evidence on the Safety and Effectiveness of Ephedra: Implications for Regulation. http://www.fda.gov/bbs/topics/NEWS/ephedra/whitepaper.html

  9. van Breemen RB, Fong HH, Farnsworth NR. Ensuring the safety of botanical dietary supplements. Am J Clin Nutr 2008;87(2):509S–513S.

    Google Scholar 

  10. Kauffman JF, Westenberger BJ, Robertson JD, Guthrie J, Jacobs A, Cummins SK. Lead in pharmaceutical products and dietary supplements. Regul Toxicol Pharmacol. 2007;48(2):128–134.

    Article  CAS  Google Scholar 

  11. Amster E, Tiwary A, Schenker MB. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environ Health Perspect 2007;115(4):606–608.

    Google Scholar 

  12. Food and Drug Administration, HHS. Center for Food Safety and Applied Nutrition, Overview of dietary supplement http://www.cfsan.fda.gov/∼dms/supplmnt.html

  13. Food and Drug Administration, HHS. Dietary Supplement and Nonprescription Drug Consumer Protection Act (Public Law 109–462) http://www.fda.gov/opacom/laws/pl109462.html

  14. Food and Drug Administration, HHS.Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule. Fed Regist. 2007 Jun 25;72(121):34751–34958.

    Google Scholar 

  15. Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults. Results from the 1999 national health interview survey. Medical Care 2002;40:353–358.

    Article  Google Scholar 

  16. Molyneaux M. The 2005 health & wellness trends databaseTM. Harleysville, PA: The Natural Marketing Institute, 2005.

    Google Scholar 

  17. Sloan E. Why people use vitamin and mineral supplements. Nutr Today 2007;42(2):55–61.

    Article  Google Scholar 

  18. Anonymous. Segment profile: vitamins & minerals. Nutr Bus J 2006;IX(2):1,3–11.

    Google Scholar 

  19. Timbo BB, Ross MP, McCarthy PV, Lin C-T.J. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 2006;106:1966–1974.

    Article  CAS  Google Scholar 

  20. Miller MF, Bellizzi KM, Sufian M, et al. Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study. J Am Diet Assoc. 2008;108(3):483–494.

    Article  Google Scholar 

  21. Grainger EM, Kim HS, Monk JP, et al. Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center. Urol Oncol 2008;26(2):125–132.

    CAS  Google Scholar 

  22. Ritchie MR. Use of herbal supplements and nutritional supplements in the UK: what do we know about their pattern of usage? Proc Nutr Soc. 2007;66(4):479–482.

    Article  CAS  Google Scholar 

  23. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008;26(4):665–673.

    Article  CAS  Google Scholar 

  24. Bardia A, Greeno E, Bauer BA. Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? J Support Oncol 2007;5(4):195–198.

    Google Scholar 

  25. Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 2007;7:4.

    Article  Google Scholar 

  26. Wittkowsky AK, Bussey HI, Walker MB, Frei CR. Dietary supplement use among anticoagulation clinic patients. J Thromb Haemost. 2007;5(4):875–877.

    Article  CAS  Google Scholar 

  27. Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis. 2008;25(1):72–77.

    Article  CAS  Google Scholar 

  28. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 27(9):1237–1247.

    Google Scholar 

  29. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006;5(3):433–451.

    Article  CAS  Google Scholar 

  30. Sood A, Sood R, Brinker FJ, Mann R, Loehrer LL, Wahner-Roedler DL. Potential for interactions between dietary supplements and prescription medications. Am J Med. 2008;121(3):207–211.

    Article  CAS  Google Scholar 

  31. Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother 2007;41:1617–1624.

    Article  Google Scholar 

  32. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mirchell AA. Recent patterns of medication use in the ambulatory adult population of the United States the Slone survey. JAMA 2002;287:337–344.

    Article  Google Scholar 

  33. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med 2005;165(3):281–286.

    Article  Google Scholar 

  34. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Mitchell AA. Use of herbal/natural supplements according to racial/ethnic group. J Altern Complement Med;12(6):555–561.

    Google Scholar 

  35. Meyer TA, Baisden CE, Roberson CR, et al. Survey of preoperative patients’ use of herbal products and other selected dietary supplements. Hosp Pharm 2002;37:1301–1306.

    Google Scholar 

  36. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999;74:443–447.

    Article  CAS  Google Scholar 

  37. Goldstein LH, Elias M, Ron-Avraham G, et al. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards. Br J Clin Pharmacol 2007;64(3):373–380.

    Article  Google Scholar 

  38. Charrois TL, Hill RL, Vu D, et al. Community identification of natural health product-drug interactions. Ann Pharmacother 2007;41:1124–1129.

    Article  Google Scholar 

  39. Chan L-N. Redefining drug–nutrient interactions. Nutr Clin Pract 2000;15(5):249–252.

    Article  Google Scholar 

  40. Ko R. Adulterants in Asian patent medicines. N Engl J Med 1998;339:847.

    Article  CAS  Google Scholar 

  41. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001;73:1101–1106.

    CAS  Google Scholar 

  42. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sports Med 2001;11:254–259.

    Article  CAS  Google Scholar 

  43. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol 2008;4(1):17–35.

    Article  CAS  Google Scholar 

  44. Nekvindová J, Anzenbacher P. Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes. Ceska Slov Farm 2007;56:165–173.

    Google Scholar 

  45. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22(12):2489–2503.

    Article  CAS  Google Scholar 

  46. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006;78(18):2105–2115.

    Article  CAS  Google Scholar 

  47. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006;62(5):512–526.

    Article  CAS  Google Scholar 

  48. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007;12(8):927–941.

    Article  Google Scholar 

  49. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006;78(18):2131–2145.

    Article  CAS  Google Scholar 

  50. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006;38(3):477–514.

    Article  CAS  Google Scholar 

  51. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36(1):57–104.

    Article  CAS  Google Scholar 

  52. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35(1):35–98.

    Article  CAS  Google Scholar 

  53. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993;24:77–97.

    Article  CAS  Google Scholar 

  54. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37(6):429–435.

    Article  Google Scholar 

  55. Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008;9(2):167–174.

    Article  CAS  Google Scholar 

  56. Knight B, Troutman M, Thakker DR. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr Opin Pharmacol 2006;6(5):528–532.

    Article  CAS  Google Scholar 

  57. Varma MV, Perumal OP, Panchagnula R. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol 2006;10(4):367–373.

    Article  CAS  Google Scholar 

  58. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70(4):317–326.

    CAS  Google Scholar 

  59. Mahady GB, Fong H, Farnsworth NR. Garlic In: Botanical dietary supplements: quality, safety and efficacy. Lisse, The Netherlands: Swets & Zeitlinger B.V, 2001: 97–114.

    Google Scholar 

  60. Rahman K. Effects of garlic on platelet biochemistry and physiology. Mol Nutr Food Res 2007;51(11):1335–1344.

    Article  CAS  Google Scholar 

  61. Ohaeri OC, Adoga GI. Anticoagulant modulation of blood cells and platelet reactivity by garlic oil in experimental diabetes mellitus. Biosci Rep 2006;26(1):1–6.

    Article  CAS  Google Scholar 

  62. Allison GL, Lowe GM, Rahman K. Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. J Nutr 2006;136(3 Suppl):782S–788S.

    CAS  Google Scholar 

  63. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci 2001;4:176–184.

    CAS  Google Scholar 

  64. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effects of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234–238.

    Article  Google Scholar 

  65. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276–287.

    Article  CAS  Google Scholar 

  66. Taubert D, Glöckner R, Müller D, Schömig E. The garlic ingredient diallyl sulfide inhibits cytochrome P450 2E1 dependent bioactivation of acrylamide to glycidamide. Toxicol Lett 2006;164(1):1–5.

    Article  CAS  Google Scholar 

  67. Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22(6):525–539.

    Article  CAS  Google Scholar 

  68. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998;54(1):7–12.

    Article  CAS  Google Scholar 

  69. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993;23(1):1–20.

    Article  CAS  Google Scholar 

  70. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003;74(2):170–177.

    Article  CAS  Google Scholar 

  71. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med 2008;74(1):19–24.

    Article  CAS  Google Scholar 

  72. Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2005;1:173–187.

    Google Scholar 

  73. Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol 2007;85(9):933–942.

    Article  CAS  Google Scholar 

  74. De Feo V, Faro C. Pharmacological effects of extracts from Valeriana adscendens Trel. II. Effects on GABA uptake and amino acids. Phytother Res 2003;17(6):661–664.

    Article  Google Scholar 

  75. Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav 2004;77(2):399–404.

    Article  CAS  Google Scholar 

  76. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7(2):265–273.

    Google Scholar 

  77. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77(5):415–426.

    Article  CAS  Google Scholar 

  78. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32(12):1333–1336.

    Article  CAS  Google Scholar 

  79. Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician 2007;76(4):549–556.

    Google Scholar 

  80. Gounder R. Kava consumption and its health effects. Pac Health Dialog. 2006;13(2):131–135.

    Google Scholar 

  81. Ernst E. Herbal remedies for anxiety – a systematic review of controlled clinical trials. Phytomedicine 2006;13(3):205–208.

    Article  CAS  Google Scholar 

  82. Anonymous. Piper methysticum (kava kava). Altern Med Rev. 1998;3(6):458–460.

    Google Scholar 

  83. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol 2004;93(2–3):153–160.

    Article  CAS  Google Scholar 

  84. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996;125(11):940–941.

    CAS  Google Scholar 

  85. Meseguer E, Taboada R, Sánchez V, et al. Life-threatening parkinsonism induced by kava-kava. Mov Disord 2002;17(1):195–196.

    Article  Google Scholar 

  86. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psych 1995;(58):639–640.

    Google Scholar 

  87. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998;31(5):187–192.

    Article  CAS  Google Scholar 

  88. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002;16(11):731–743.

    Article  Google Scholar 

  89. Yuan CS, Dey L, Wang A, et al. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med 2002;68(12):1092–1096.

    Article  CAS  Google Scholar 

  90. Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner W. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 2001;67(4):306–311.

    Article  CAS  Google Scholar 

  91. Martin HB, McCallum M, Stofer WD, Eichinger MR. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med 2002;68:784–789.

    Article  CAS  Google Scholar 

  92. Gleitz J, Friese J, Beile A, Ameri A, Peters T. Anticonvulsive action of (+/–)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996;315(1):89–97.

    Article  CAS  Google Scholar 

  93. Anke J, Ramzan I. Kava Hepatotoxicity: Are we any closer to the truth? Planta Med 2004;70(3):193–196.

    Article  CAS  Google Scholar 

  94. Fu PP, Xia Q, Guo L, Yu H, Chan PC. Toxicity of kava kava. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008;26(1):89–112.

    CAS  Google Scholar 

  95. Lechtenberg M, Quandt B, Schmidt M, Nahrstedt A. Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Pharmazie 2008;63(1):71–74.

    CAS  Google Scholar 

  96. Ulbricht C, Basch E, Boon H, et al. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf 2005;4(4):779–794.

    Article  Google Scholar 

  97. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005;39(4 Suppl 2):S83–89.

    Article  Google Scholar 

  98. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and the kava-kava controversy. Phytochemistry 2003;64(3):673–679.

    Article  CAS  Google Scholar 

  99. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003;10(5):440–446.

    Article  CAS  Google Scholar 

  100. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003;138(8):852–858.

    Article  Google Scholar 

  101. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003;41(2):109–113.

    Article  CAS  Google Scholar 

  102. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003;178(9):442–443.

    Google Scholar 

  103. Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust 2003;178(9):421–422.

    Google Scholar 

  104. The Food and Drug Administration, Center for Food Safety and Applied Nutrition. Letter to Health Care Professionals about FDA Seeking Information on Liver Injury and Kava Products. December 19, 2001. http://www.cfsan.fda.gov/∼dms/ds-ltr27.html

  105. Mahady GB, Fong H, Farnsworth NR. Ginko biloba. In: Botanical dietary supplements: quality, safety and efficacy. Lisse, The Netherlands: Swets & Zeitlinger B.V, 2001:140–158.

    Google Scholar 

  106. Rosenblatt M. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108.

    Article  CAS  Google Scholar 

  107. Matthews M. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933.

    Google Scholar 

  108. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of ginkgolide mixture (BN52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987;1:248–1251.

    Article  CAS  Google Scholar 

  109. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352:36.

    Article  CAS  Google Scholar 

  110. Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004;27(12):2006–2009.

    Article  CAS  Google Scholar 

  111. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006;13(1):24–31.

    Article  Google Scholar 

  112. Aruna D, Naidu MU. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007;63(3):333–338.

    Article  CAS  Google Scholar 

  113. Mahady GB, Fong H, Farnsworth NR. St. John’s wort. In: Botanical dietary supplements: quality, safety and efficacy. Lisse, The Netherlands: Swets & Zeitlinger B.V, 2001:245–261.

    Google Scholar 

  114. Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000448.

    Google Scholar 

  115. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am 2007;30(1):51–68.

    Article  Google Scholar 

  116. Charrois TL, Sadler C, Vohra S. American academy of pediatrics provisional section on complementary, holistic, and integrative medicine: St. John’s wort. Pediatr Rev 2007;28(2):69–72.

    Article  Google Scholar 

  117. Lawvere S, Mahoney MC. St. John’s wort. Am Fam Physician 2005;72(11):2249–2254.

    Google Scholar 

  118. Bergonzi MC, Bilia AR, Gallori S, Guerrini D, Vincieri FF. Variability in the content of constituents of hypericum perforatum L. and some commercial extracts. Drug Dev Indus Pharm 2001;27:491–497.

    Article  CAS  Google Scholar 

  119. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006;62(5):512–526.

    Article  CAS  Google Scholar 

  120. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John’s wort drug interactions. Eur J Clin Pharmacol 2006;62(3):225–233.

    Article  CAS  Google Scholar 

  121. Xie HG, Kim RB. St John’s wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 2005;78(1):19–24.

    Article  CAS  Google Scholar 

  122. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther 2003;73(1):41–50.

    Article  CAS  Google Scholar 

  123. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John’s wort. Lancet 2000;355(9203):547–548.

    Article  CAS  Google Scholar 

  124. Durr D, Steiger B, Kullak-Ublick GA, et al. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP 3A4. Clin Pharmacol Ther 2000;68:598–604.

    Article  CAS  Google Scholar 

  125. Moore LB Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of pregnane X receptor. Proc Natl Acad Sci USA 2000;97(13):7500–7502.

    Article  CAS  Google Scholar 

  126. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413–580.

    Google Scholar 

  127. Fogle RH, Murphy PA, Westhoff CL, Stanczyk FZ. Does St. John’s wort interfere with the antiandrogenic effect of oral contraceptive pills? Contraception 2006;74(3):245–248.

    Article  CAS  Google Scholar 

  128. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John’s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71(6):402–408.

    Article  CAS  Google Scholar 

  129. Hall SD, Wang Z, Huang SM, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003;74(6):525–535.

    Article  CAS  Google Scholar 

  130. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56(6):683–690.

    Article  CAS  Google Scholar 

  131. Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. Geriatr Psychiatry Neurol 1999;12(1):7–10.

    Article  CAS  Google Scholar 

  132. Gordon JB. SSRI’s and St. John’s wort: possible toxicity? Am Fam Phys 1998;57:950–953.

    CAS  Google Scholar 

  133. Gregory PJ, Sperry M, Wilson AF. Dietary supplements for osteoarthritis. Am Fam Physician 2008;77(2):177–184.

    Google Scholar 

  134. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24(7):573–580.

    Article  CAS  Google Scholar 

  135. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology(Oxford) 2007;46(5):731–735.

    Article  CAS  Google Scholar 

  136. Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006;354(8):841–848.

    Article  CAS  Google Scholar 

  137. Curtis CL, Harwood JL, Dent CM, Caterson B. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today 2004;9(4):165–172.

    Article  CAS  Google Scholar 

  138. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 2006;45(2):129–138.

    Article  CAS  Google Scholar 

  139. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008;148(4):268–277.

    Google Scholar 

  140. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354(8):795–808.

    Article  CAS  Google Scholar 

  141. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy 2008;28(4):540–548.

    Google Scholar 

  142. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 2005;130:777–780.

    Article  Google Scholar 

  143. Scott GN. Interaction of warfarin with glucosamine – chondroitin. Am J Health Syst Pharm 2004;61(11):1186.

    Google Scholar 

  144. Rozenfeld V, Crain JL, Callahan AK. Possible augmentation of warfarin effect by glucosamine-chondroitin. Am J Health Syst Pharm 2004;61(3):306–307.

    Google Scholar 

  145. Attele AS, Wu JA, Yuan C. Ginseng pharmacology multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685–1693

    Article  CAS  Google Scholar 

  146. Coon JT, Ernst E. Panax ginseng a systematic review of adverse effects and drug interactions. Drug Safety 2002;25:323–344.

    Article  CAS  Google Scholar 

  147. O’Hara M, Kiefer D, Farrell K, et al. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998;7:523–536.

    Article  Google Scholar 

  148. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm 1997;54:692–693.

    CAS  Google Scholar 

  149. Zhu M, Chan KW, NG LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999;51:175–180.

    Google Scholar 

  150. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43(6):643–648.

    Google Scholar 

  151. Liu Y, Zhang JW, Li W, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006;91(2):356–364.

    Article  CAS  Google Scholar 

  152. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology 2003;99(2):111.

    Article  Google Scholar 

  153. Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled Trial. Ann Intern Med 2004;141(1):23–27.

    CAS  Google Scholar 

  154. Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57(5):592–599. (Erratum in: Br J Clin Pharmacol 2004;58(1):102.

    Article  CAS  Google Scholar 

  155. Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. J Clin Psychopharm 1985;5:65.

    Article  CAS  Google Scholar 

  156. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharm 1987;3:201–202.

    Article  Google Scholar 

  157. Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. J Clin Psychopharm 1988;8:235.

    CAS  Google Scholar 

  158. Becker BN, Greene J, Evanson J, et al. Ginseng-induced diuretic resistance [letter]. JAMA 1996;276:606–607.

    Article  CAS  Google Scholar 

  159. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726–735.

    CAS  Google Scholar 

  160. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M. Phenytoin-folic acid interaction: a lesson to be learned. Clin Neuropharmacol 1999;22(5):268–272.

    CAS  Google Scholar 

  161. Sokol RJ, Johnson KE, Karrer FM, et al. Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991;338:212–215.

    Article  CAS  Google Scholar 

  162. Boudreaux JP, Hayes DH, Mizrahi S, et al. Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. Transplant Proc 1993;25(2):1875.

    CAS  Google Scholar 

  163. Pan S, Lopez RR, Sher LS, et al. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation. Pharmacotherapy 1996;16(1):59–65.

    CAS  Google Scholar 

  164. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999;16(10):1550–1556

    Article  CAS  Google Scholar 

  165. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4(4):40.

    Article  Google Scholar 

  166. Chan L, Humma LM, Schriever CA, Fashingbauer LA, Dominguez CP, Baum CL. Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-gp) in humans. [Abstract] Clin Pharmacol Ther 2004;75(2):P95 (PDII-B1).

    Article  Google Scholar 

  167. Jalili M, Dehpour AR. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids. Arch Med Res 2007;38(8):901–904.

    Article  CAS  Google Scholar 

  168. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 2007;27(1):152–160.

    Google Scholar 

  169. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother 2004;38(1):50–52.

    Article  Google Scholar 

  170. Pai AB, Norenberg J, Boyd A, Raj D, Chan LN. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study. Clin Ther 2007;29(12):2699–2705.

    Article  CAS  Google Scholar 

  171. Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John’s wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 2007;41:229–234.

    Article  CAS  Google Scholar 

  172. Bell EC, Ravis WR, Chan HM, Lin YJ. Lack of pharmacokinetic interaction between St. John’s wort and prednisone. Ann Pharmacother 2007;41:1819–1824.

    Article  CAS  Google Scholar 

  173. Gelone DK, Park JM, Lake KD. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. Pharmacotherapy 2007;27:1272–1278.

    Article  CAS  Google Scholar 

  174. Butterweck V, Derendorf H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet 2008;47:383–397.

    Article  CAS  Google Scholar 

  175. U.S. Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting pogram. Revised May 30 2008. http://www.fda.gov/medwatch/index.html. Accessed May 30 2008.

  176. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41(4):674–680.

    Article  Google Scholar 

  177. Boullata J. Natural health product interactions with medication. Nutr Clin Pract 2005;20(1):33–51.

    Article  Google Scholar 

  178. Haller C, Kearney T, Bent S, et al. Dietary supplement adverse events: report of a one-year poison center surveillance project. J Med Toxicol. 2008;4(2):84–92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Washington, Seattle, WA, USA

    Lingtak-Neander Chan PharmD, BCNSP (Associate Professor of Pharmacy)

Authors
  1. Lingtak-Neander Chan PharmD, BCNSP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Nursing, University of Pennsylvania, Guardian Dr. 420, Philadelphia, 19104, U.S.A.

    Joseph I. Boullata

  2. Dept. Surgery, Temple University Hospital, N. Broad St. 3401, Philadelphia, 19140, U.S.A.

    Vincent T. Armenti

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chan, LN. (2009). Interaction of Natural Products with Medication and Nutrients. In: Boullata, J., Armenti, V. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-362-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-362-6_12

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-363-3

  • Online ISBN: 978-1-60327-362-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation